Proliferatif endometriyum, endometriyal hiperplazi ve endometrioid endometriyal karsinomda CYP3A4 immünohistokimyasal ekspresyonunun karşılaştırılması

Abstract

Amaç: Karşılanmamış kronik östrojen maruziyeti, endometriyum kanserinin gelişmesinden sorumludur. Sitokrom P450 3A4 (CYP3A4), östradiolü dokularda daha zayıf östrojenik etkilere sahip metabolitlere dönüştürür. Bu etki, dokuları östrojenin zararlı etkilerinden koruyabilir. Bu çalışmada, CYP3A4 enzimi ile endometriyum kanseri arasındaki ilişki araştırılmıştır. Gereç ve Yöntemler: Proliferatif endometriyum, endometriyal hiperplazi ve endometrioid adenokarsinom tanısı konmuş toplam 60 kadın çalışmaya dahil edildi. Endometriyal bez ve stroma, CYP3A4 enzim ekspresyonu için immünohistokimyasal boyama ile değerlendirildi. Bulgular: CYP3A4 ile glandüler boyama, hastalığın seyriyle tutarlı olarak endometriyal kanser grubunda en yoğundu. Ayrıca, stromal boyanma yüzdesi endometriyal kanser grubunda proliferatif endometriyum grubuna göre daha düşüktü. Glandüler boyanma yüzdesi ve stromal yoğunluk tüm gruplarda benzerdi. Sonuç: CYP3A4 ekspresyonu, malign transformasyon sırasında endometriyal bezlerde artmaktadır. Bunun kesin rolü belirsiz olmakla birlikte, bu durum kronik östrojen maruziyetine karşı bir kompansatuar yanıtı yansıtıyor olabilir.

Keywords

• CYP3A4
• Endometriyal hiperplazi
• Endometriyal karsinom
• Östrojen metabolizması
• İmmünohistokimya.

Comparison of CYP3A4 immunohistochemical expression in proliferative endometrium, endometrial hyperplasia, and endometrioid endometrial carcinoma

Abstract

Aim: Unopposed chronic estrogen exposure is responsible for the development of endometrial cancer. Cytochrome P450 3A4 (CYP3A4) converts estradiol into metabolites with weaker estrogenic effects in tissues. This effect may protect tissues against the harmful effects of estrogen. In this study, the relationship between the CYP3A4 enzyme and endometrial cancer was investigated. Material and Methods: A total of 60 women diagnosed with proliferative endometrium, endometrial hyperplasia, and endometrioid adenocarcinoma were included in the study. The endometrial gland and stroma expression were evaluated by immunohistochemical staining for the CYP3A4 enzyme. Results: Glandular staining with CYP3A4 was most intense in the endometrial cancer group, consistent with the course of the disease. Moreover, the stromal staining percentage was lower in the endometrial cancer group than in the proliferative endometrium group. The glandular staining percentage and stromal intensity were similar in all groups. Conclusion: CYP3A4 expression is increased in endometrial glands during malignant transformation. This may reflect a compensatory response to chronic estrogen exposure, although its exact role remains unclear.

Keywords

• CYP3A4
• Endometrial hyperplasia
• Endometrial carcinoma
• Estrogen metabolism
• Immunohistochemistry.

References

1. Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. Cancers (Basel). 2020;12(8):2195. https://doi.org/10.3390/cancers12082195
2. Eijk MV, Beijnen JH, Boosman RJ, Huitema ADR, Schinkel AH. Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to Taxanes. Cancer Chemother. Pharmacol. 2019;84:487-499. https://doi.org/10.1007/s00280-019-03905-3
3. Zheng Y, Xu Y, Zhou BY, Sun L, Yu PB, Zhang L, et al. CYP3A4-1B polymorphism and cancer risk: a meta-analysis based on 55 case-control studies. Ann Clin Lab Sci. 2018;48(4):538-545. PMID: 30143500.
4. Audet-Delage Y, Grégoire J, Caron P, Turcotte V, Plante M, Ayotte P, et al. Estradiol metabolites as biomarkers of endometrial cancer prognosis after surgery. J Steroid Biochem Mol Biol. 2018;178:45-54. https://doi.org/10.1016/j.jsbmb.2017.10.021
5. Shou M, Brooks EN, Gelboin HV, Gonzalez FJ, Korzekwa KR, Krausz KW. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis. 1997; 207-14. https://doi.org/10.1093/carcin/18.1.207
6. Stipp MC, Acco A. Involvement of cytochrome P450 enzymes in inflammation and cancer: a review. Cancer Chemotherapy and Pharmacology. 2021;87(3):295-309. https://doi.org/10.1007/s00280-020-04181-2
7. Sarkar MA, Glover DD, Ghosh S, Vadlamuri V. Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos. 2003;31(1):1-6. https://doi.org/10.1124/dmd.31.1.1
8. Nucii MR, Oliva E. Foundation in Diagnostic Pathology. In: Goldblum JR. Gynecologic Pathology, 1st ed, United Kingdom: Elsevier Churchill Livingstone. 2009;197: 234-242.

9. Mokhosoev IM, Astakhov DV, Terentiev AA, Moldogazieva NT. Human cytochrome P450 cancer-related metabolic activities and gene polymorphisms: A review. Cells. 2024;13(23):1958. https://doi.org/10.3390/cells13231958
10. Masuyama H, Hiramatsu Y, Kodama JI, Kudo T. Expression and potential roles of pregnane X receptor in endometrial cancer. J Clin Endocrinol Metab. 2003;88:4446-4454. https://doi.org/10.1210/jc.2003-030203
11. Floriano-Sanchez E, Rodriguez NC, Bandala C, Coballase-Urrutia E, Lopez-Cruz J. CYP3A4 expression in breast cancer and its association with risk factors in Mexican women. Asian Pac J Cancer Prev. 2014;15(8):3805-3809. https://doi.org/10.7314/APJCP.2014.15.8.3805
12. Bulbul M, Aydın Turk B, Karaçor T, Onderci M, Nacar MC, Parlar A, et al. Carbamazepine protects the endometrium against negative effects of estrogen in rats. Biotech Histochem. 2022;97(4):254-260. https://doi.org/10.1080/10520295.2021.1942988
13. Chu W, Fyles A, Sellers EM, McCready DR, Murphy J, Pal T, et al. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis. 2007;28(10):2139-42. https://doi.org/10.1093/carcin/bgm087
14. Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol. 2002 Aug;62(2):359-65. https://doi.org/10.1124/mol.62.2.359
15. Meduri GU. Factors influencing glucocorticoid treatment response: mechanism-based strategies to overcome glucocorticoid resistance and restore grα function. Semin Respir Crit Care Med. 2026;47(1):47-65. https://doi.org/10.1055/a-2691-6206
16. Jover R, Moya M, Gómez-Lechón MJ. Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. Curr Drug Metab. 2009;10(5):508-519. https://doi.org/10.2174/138920009788898000
17. Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 2002;16(13):1799-1801. https://doi.org/10.1096/fj.02-0195fje
18. Alshakarchi HI, Azari H, Jeddoa ZMA, Jafar NNA, Khazaei Y, Gataa IS, et al. Metabolic targets in CRC: the emerging role of cytochrome P450 inhibitors. Current Pharmaceutical Design. 2025;31(42):3365-3389. https://doi.org/10.2174/0113816128341167250520063502
19. Rajakumar T, Pugalendhi P. Allyl isothiocyanate regulates oxidative stress, inflammation, cell proliferation, cell cycle arrest, apoptosis, angiogenesis, invasion and metastasis via interaction with multiple cell signaling pathways. Histochem. Cell Biol. 2024;161(3):211-221. https://doi.org/10.1007/s00418-023-02255-9
20. Piergentili R, Marinelli E, De Paola L, Cucinella G, Billone V, Zaami S, et al. Epigenetics of endometrial cancer: The role of chromatin modifications and medicolegal implications. Int J Mol Sci 2025;26(15):7306. https://doi.org/10.3390/ijms26157306
21. Cai Y, Wang B, Xu W, Liu K, Gao Y, Guo C, Chen J, Kamal MA,Yuan, C. Endometrial cancer: genetic, metabolic characteristics, therapeutic strategies and nanomedicine. Curr. Med. Chem. 2021;28(42): 8755-8781. https://doi.org/10.2174/0929867328666210705144456
22. Jayawickcrama WIU, Abeysena C. Risk factors for endometrial carcinoma among postmenopausal women in Sri Lanka: a case control study. BMC Public Health. 2019;19:1387. https://doi.org/10.1186/s12889-019-7757-2
23. Mills AM, Longacre TA. Endometrial hyperplasia. Semin Diagn Pathol. 2010;27(4):199-214. https://doi.org/10.1053/j.semdp.2010.09.002